Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans
Abstract
:1. Introduction
2. Results and Discussion
2.1. Regimen of CMX001 Required for Protection from Rabbitpox virus (RPV) Disease and Death
2.2. Randomized, Blinded, Placebo Controlled Studies
2.3. Rabbitpox Infection via Natural Aerosol Model Review
2.4. Treatment of Natural Aerosol Infected Animals
3. Experimental Section
3.1. Cell and Virus Growth
3.2. Housing of Animals
3.3. Animal Infections
3.4. Monitoring of Animals
3.5. CMX001 Dosing of Animals
4. Conclusions
Acknowledgements
References and Notes
- FDA grants marketing clearance of Vistide for the treatment of CMV retinitis. AIDS Patient Care STDS 1996, 10, 383–384.
- Food and Drug Administration. FDA approves cidofovir for treatment of CMV retinitis. J. Int. Assoc. Phys. AIDS Care 1996, 2, 30. [Google Scholar]
- Bray, M.; Martinez, M.; Smee, D.F.; Kefauver, D.; Thompson, E.; Huggins, J.W. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 2000, 181, 10–19. [Google Scholar] [CrossRef]
- Smee, D.F.; Sidwell, R.W.; Kefauver, D.; Bray, M.; Huggins, J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46, 1329–1335. [Google Scholar] [CrossRef] [PubMed]
- Baker, R.; Bray, M.; Huggins, J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antivir. Res. 2003, 57, 13–23. [Google Scholar] [CrossRef]
- Kornbluth, R.S.; Smee, D.F.; Sidwell, R.W.; Snarsky, V.; Evans, D.H.; Hostetler, K.Y. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 2006, 50, 4038–4043. [Google Scholar] [CrossRef]
- Magee, W.C.; Hostetler, K.Y.; Evans, D.H. Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob. Agents Chemother. 2005, 49, 3153–3162. [Google Scholar] [CrossRef]
- Araya, C.E.; Lew, J.F.; Fennell, R.S.; Neiberger, R.E.; Dharnidharka, V.R. Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr. Transplant. 2008, 12, 790–795. [Google Scholar] [CrossRef]
- Ciesla, S.L.; Trahan, J.; Wan, W.B.; Beadle, J.R.; Aldern, K.A.; Painter, G.R.; Hostetler, K.Y. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res. 2003, 59, 163–171. [Google Scholar] [CrossRef]
- Painter, G.R.; Hostetler, K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol. 2004, 22, 423–427. [Google Scholar] [CrossRef]
- Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, A.; Ladnyi, I.D. Smallpox and Its Eradication; World Health Organization: Geneva, Switzerland, 1988. [Google Scholar]
- Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox Virus and Vaccinia Virus Infection of Rabbits as a Model for Human Smallpox. J. Virol. 2007, 81, 11084–11095. [Google Scholar] [CrossRef] [PubMed]
- Nalca, A.; Hatkin, J.M.; Garza, N.L.; Nichols, D.K.; Norris, S.W.; Hruby, D.E.; Jordan, R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir. Res. 2008, 79, 121–127. [Google Scholar] [CrossRef] [PubMed]
- Garza, N.L.; Hatkin, J.M.; Livingston, V.; Nichols, D.K.; Chaplin, P.J.; Volkmann, A.; Fisher, D.; Nalca, A. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 2009, 27, 5496–5504. [Google Scholar] [CrossRef] [PubMed]
- Roy, C.J. Rabbitpox: An Aerosol Model for the Study of Aerosolized Poxviruses. J. Antivir. Res. 2004, 43, S34. [Google Scholar]
- Roy, C.J.; Nichols, D.K. Pathology of aerosolized rabbitpox virus infection in rabbits. Vet. Pathol. 2006, 14, 289–300. [Google Scholar]
- Foster, S. Chimerix, Inc., Durham, NC, USA. Unpublished work. 2010. [Google Scholar]
- Ho, H.T.; Woods, K.L.; Bronson, J.J.; De, B.H.; Martin, J.C.; Hitchcock, M.J. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 1992, 41, 197–202. [Google Scholar]
- Rice, A.D.; Adams, M.M.; Lampert, B.; Foster, S.; Lanier, R.; Robertson, A.; Painter, G.; Moyer, R.W. Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses 2011, in press. [CrossRef]
- Rice, A.D.; Moyer, R.W. University of Florida, Gainesville, FL, USA. Unpublished work. 2009. [Google Scholar]
- Rice, A.D.; Moyer, R.W. University of Florida, Gainesville, FL, USA. Unpublished work. 2010. [Google Scholar]
- Westwood, J.C.; Boulter, E.A.; Bowen, E.T.; Maber, H.B. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol. 1966, 47, 453–465. [Google Scholar]
- Fenner, F.; Henderson, D. A.; Arita, I.; Jezek, Z.; Ladnyi, I. D. The pathogenesis, pathology and immunology of smallpox and vaccinia. In Smallpox and Its Eradication; World Health Organization: Geneva, Switzerland, 1988; pp. 121–168. [Google Scholar]
- Rao, A.R. Smallpox; The Kothari Book Depot: Bombay, India, 1972. [Google Scholar]
- Martin, D.B. The cause of death in smallpox: An examination of the pathology record. Mil. Med. 2002, 167, 546–551. [Google Scholar] [CrossRef]
- Condit, R.C.; Motyczka, A. Isolation and preliminary characterization of temperature- sensitive mutants of vaccinia virus. Virology 1981, 113, 224–241. [Google Scholar] [CrossRef]
- Condit, R.C.; Motyczka, A.; Spizz, G. Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus. Virology 1983, 128, 429–443. [Google Scholar] [CrossRef] [PubMed]
CMX001 Dose (mg/kg) | Day of Dosing (dpi) | Mean Time to Death ± SEM | Survival at Day 14PI |
---|---|---|---|
20 | 3 | NA | 3/3 (100%)* |
20 | 4 | 10 ± 0 | 2/3 (66%) |
20 | 3, 5 | NA | 3/3 (100%)* |
20 | 4, 6 | 7 ± 0 | 2/3 (66%) |
20 | 3, 5, 7 | NA | 3/3 (100%)* |
20 | 4, 6, 8 | 9 ± 0 | 2/3 (66%) |
Vehicle | Vehicle | 9 ± 0 | 0/2 (0%) |
CMX001 Dose (mg/kg) | Frequency of Dosing | Day Dosing Began (dpi) | Mean Time to Death ± SEM | Survival at Day 14PI |
---|---|---|---|---|
20 | 1 dose | 3 to 4 | 10.6 ± 0.24 | 7/12 (58.33%) |
20 | 2 doses | 3 to 5 | 10.5 ± 0.96 | 8/12 (67.67%) |
20 | 3 doses | 3 to 4 | 11 ± 0 | 11/12 (91.67%) |
Vehicle | NA | 3 to 4 | 9.06 ± 0.18 | 4/36 (11.1%) |
CMX001 Dose (mg/kg) | Frequency of Dosing | Day Dosing Began (dpi) | Mean Time to Death ± SEM | Survival at Day 14PI |
---|---|---|---|---|
20 | 1 dose | 7 to 8 | 18 ± 0 | 2/3 (66%) |
20 | 2 doses | 7 to 9 | 13 ± 0 | 2/3 (66%) |
20 | 3doses | 7 to 9 | 16 ± 0 | 2/3 (66%) |
Vehicle | NA | NA | 14.3 ± 1.3 | 0/3 (0%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2011 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rice, A.D.; Adams, M.M.; Wallace, G.; Burrage, A.M.; Lindsey, S.F.; Smith, A.J.; Swetnam, D.; Manning, B.R.; Gray, S.A.; Lampert, B.; et al. Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses 2011, 3, 47-62. https://doi.org/10.3390/v3010047
Rice AD, Adams MM, Wallace G, Burrage AM, Lindsey SF, Smith AJ, Swetnam D, Manning BR, Gray SA, Lampert B, et al. Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses. 2011; 3(1):47-62. https://doi.org/10.3390/v3010047
Chicago/Turabian StyleRice, Amanda D., Mathew M. Adams, Greg Wallace, Andrew M. Burrage, Scott F. Lindsey, Andrew J. Smith, Daniele Swetnam, Brandi R. Manning, Stacey A. Gray, Bernhard Lampert, and et al. 2011. "Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans" Viruses 3, no. 1: 47-62. https://doi.org/10.3390/v3010047
APA StyleRice, A. D., Adams, M. M., Wallace, G., Burrage, A. M., Lindsey, S. F., Smith, A. J., Swetnam, D., Manning, B. R., Gray, S. A., Lampert, B., Foster, S., Lanier, R., Robertson, A., Painter, G., & Moyer, R. W. (2011). Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans. Viruses, 3(1), 47-62. https://doi.org/10.3390/v3010047